Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2018

Open Access 01-08-2018 | Commentary

An historical overview over Pharmacovigilance

Authors: Giulia Fornasier, Sara Francescon, Roberto Leone, Paolo Baldo

Published in: International Journal of Clinical Pharmacy | Issue 4/2018

Login to get access

Abstract

Pharmacovigilance started about 170 years ago, although it was not yet named as such at that time. It is structured activity in the professional health field, with important social and commercial implications aimed at monitoring the risk/benefit ratio of drugs, improving patient’s safety and the quality of life. In this commentary we report the milestones of pharmacovigilance up to the present day, in order to understand all the steps that have characterized the historical evolution; from the first reports, which were essentially letters or warnings sent by clinicians to publishers of important and famous scientific journals, up to today’s modern and ultra-structured electronic registries. The historical phases also help us to understand why pharmacovigilance helped us to achieve such important results for man’s health and for pharmacology itself, and to identify the challenges that await Pharmacovigilance in future years.
Literature
2.
go back to reference Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review. Expert Opin Drug Saf. 2018;17:63–72.CrossRef Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review. Expert Opin Drug Saf. 2018;17:63–72.CrossRef
3.
4.
go back to reference Commission on Anaesthetics. Lancet. 1893; i:629–38. Commission on Anaesthetics. Lancet. 1893; i:629–38.
5.
go back to reference Woolf AD. The Haitian diethylene glycol poisoning tragedy: a dark wood revisited. JAMA. 1998;279:1215–6.CrossRef Woolf AD. The Haitian diethylene glycol poisoning tragedy: a dark wood revisited. JAMA. 1998;279:1215–6.CrossRef
8.
go back to reference Douthwaite AH. Some recent advances in medical diagnosis and treatment. Br Med J. 1938;1:1143.CrossRef Douthwaite AH. Some recent advances in medical diagnosis and treatment. Br Med J. 1938;1:1143.CrossRef
9.
go back to reference Levy M. The epidemiological evaluation of major upper gastrointestinal bleeding in relation to aspirin use. In: Kewitz H, Roots I, Voigt K, editors. Epidemiological concepts in clinical pharmacology. Berlin: Springer; 1987. p. 100–4.CrossRef Levy M. The epidemiological evaluation of major upper gastrointestinal bleeding in relation to aspirin use. In: Kewitz H, Roots I, Voigt K, editors. Epidemiological concepts in clinical pharmacology. Berlin: Springer; 1987. p. 100–4.CrossRef
10.
go back to reference McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961; ii:1358. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961; ii:1358.
11.
go back to reference Lenz W, Knapp K. Foetal malformations due to Thalidomide. German Med. 1962;7:253–8. Lenz W, Knapp K. Foetal malformations due to Thalidomide. German Med. 1962;7:253–8.
12.
go back to reference Kajii T, Kida M, Takahashi K. The effect of thalidomide intake during 113 human pregnancies. Teratology. 1973;8:163–6.CrossRef Kajii T, Kida M, Takahashi K. The effect of thalidomide intake during 113 human pregnancies. Teratology. 1973;8:163–6.CrossRef
Metadata
Title
An historical overview over Pharmacovigilance
Authors
Giulia Fornasier
Sara Francescon
Roberto Leone
Paolo Baldo
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2018
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-018-0657-1

Other articles of this Issue 4/2018

International Journal of Clinical Pharmacy 4/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.